Congress has a window to keep coverage affordable by extending enhanced premium tax credits. Delay means higher 2026 costs for millions of families. Details from AHIP: bit.ly/4gpb71i

Provider consolidation + growing demand for GLP-1s are shaping tomorrow’s premiums. The time to act is today to protect affordability in 2026. Read AHIP’s analysis: bit.ly/4gpb71i

AHIP warns 2026 premiums face pressure from medical inflation, drug costs, regulatory shifts & a potential end to enhanced tax credits—with Open Enrollment on Nov 1. Meanwhile, CSRxP: generics/biosimilars saved $467B in 2024. Congress should act. 🔗 bit.ly/4gpb71i

📊 A national NORC survey of ~700 employers finds strong satisfaction with PBMs—on transparency, flexibility & savings. PBMs help manage drug costs while employers tailor benefits to their workforce. Learn more: bit.ly/42lMEnI

A new report looks at the impact that mandates targeting the tools deployed by PBMs to control costs for their customers would have on employers and health plans – in other words, limiting choice and adding new administrative costs. Learn more here: bit.ly/4t8jhAW